Advertisement

Path to Clinical Trials: Trial Design, Development of the Clinical Product, and Safety Concerns in the Implementation of Clinical Trials

  • Jerry R. MendellEmail author
  • Louise R. Rodino-Klapac
  • Christopher J. Shilling
Chapter

Abstract

The path to an IND from conception of a potentially promising mode of treatment to a clinical trial is often not fully understood. This chapter attempts to provide a template from early considerations, through safety concerns and product development. The regulatory agencies play a major role in this process and are often accessible to advise researchers about specific issues that may be relevant in the planning phase. The message from this chapter is that if researchers want to pursue clinical translation, it should be considered even before any preclinical studies are done. This will save both time and funds and avoid duplication and modifying previous experiments that showed promise but had not satisfied regulatory requirements. The preclinical studies must consider the vector used in gene delivery, dosing, and safety issues that are applicable to clinical trial. Taking advantage of opportunities to explore toxicity to the fullest for later presentation to regulatory agencies is an important consideration. The pre-IND meeting with the FDA is a pivotal step to get to a clinical trial and will provide a template to follow in preparation and planning for the IND. All of the agencies that are critical to the translation process are fully described in this chapter for fulfilling commitments to bring promising experiments from the laboratory to the clinic.

Keywords

IND FDA Adeno-associated virus (AAV) Toxicology Clinical trial 

References

  1. 1.
    Somia N, Verma IM (2000) Gene therapy: trials and tribulations. Nat Rev Genet 1(2):91–99.  https://doi.org/10.1038/35038533 CrossRefPubMedGoogle Scholar
  2. 2.
    Stolberg SG (1999) The biotech death of Jesse Gelsinger. N Y Times Mag: 136–140, 149–150Google Scholar
  3. 3.
    Gore M (2003) Gene therapy can cause leukaemia: no shock, mild horror but a probe. Gene Ther 10:4.  https://doi.org/10.1038/sj.gt.3301946 CrossRefGoogle Scholar
  4. 4.
    Cavazzana-Calvo M (2013) Gene therapy: where do we stand? Rev Prat 63(4):457–461PubMedGoogle Scholar
  5. 5.
    Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669–672CrossRefGoogle Scholar
  6. 6.
    Kaiser J (2007) Clinical trials. Gene transfer an unlikely contributor to patient’s death. Science 318(5856):1535.  https://doi.org/10.1126/science.318.5856.1535 CrossRefPubMedGoogle Scholar
  7. 7.
    Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR (2018) Gene therapy clinical trials worldwide to 2017 - an update. J Gene Med 20(5):e3015.  https://doi.org/10.1002/jgm.3015 CrossRefPubMedGoogle Scholar
  8. 8.
    Williams DA (2007) RAC reviews serious adverse event associated with AAV therapy trial. Mol Ther 15(12):2053–2054.  https://doi.org/10.1038/sj.mt.6300352 CrossRefPubMedGoogle Scholar
  9. 9.
    Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583–593.  https://doi.org/10.1128/CMR.00008-08 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1714–1722.  https://doi.org/10.1056/NEJMoa1706198 CrossRefGoogle Scholar
  11. 11.
    Reich SJ, Auricchio A, Hildinger M, Glover E, Maguire AM, Wilson JM, Bennett J (2003) Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum Gene Ther 14(1):37–44.  https://doi.org/10.1089/10430340360464697 CrossRefPubMedGoogle Scholar
  12. 12.
    Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W, Mansfield SG, Mitchell LG, Engelhardt JF (2005) Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther 16(9):1116–1123.  https://doi.org/10.1089/hum.2005.16.1116 CrossRefPubMedGoogle Scholar
  13. 13.
    Ghosh A, Yue Y, Duan D (2006) Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med 8(3):298–305.  https://doi.org/10.1002/jgm.835 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN, Shontz KM, Montgomery CL, Liu J, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR (2015) AAV.Dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol 2(3):256–270.  https://doi.org/10.1002/acn3.172 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68(5):629–638.  https://doi.org/10.1002/ana.22251 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, Craenen JM, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Viollet L, Walker CM, Sahenk Z, Clark KR (2009) Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 66(3):290–297.  https://doi.org/10.1002/ana.21732 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Viollet L, Gailey S, Thornton DJ, Friedman NR, Flanigan KM, Mahan JD, Mendell JR (2009) Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 40(3):438–442.  https://doi.org/10.1002/mus.21420 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rosales XQ, Chu ML, Shilling C, Wall C, Pastores GM, Mendell JR (2008) Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage. J Child Neurol 23(7):748–751.  https://doi.org/10.1177/0883073808314365 CrossRefPubMedGoogle Scholar
  19. 19.
    FDA (2006) Guidance for industry: supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectorsGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jerry R. Mendell
    • 1
    • 2
    Email author
  • Louise R. Rodino-Klapac
    • 1
    • 3
  • Christopher J. Shilling
    • 4
  1. 1.Departments of Pediatrics, Nationwide Children’s Hospital and Research InstituteThe Ohio State UniversityColumbusUSA
  2. 2.Department of Neurology, Nationwide Children’s Hospital and Research InstituteThe Ohio State UniversityColumbusUSA
  3. 3.Vice President Gene TherapySarepta TherapeuticsColumbusUSA
  4. 4.Drug and Device Developmental Services, Nationwide Children’s Hospital and Research InstituteThe Ohio State UniversityColumbusUSA

Personalised recommendations